FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386001080> ?p ?o ?g. }

• W4386001080 abstract "A 67-year-old man using nilotinib 300 mg twice a day to treat chronic myeloid leukemia for 3 years, with major molecular response, presented with sudden-onset left-sided paresis in the limbs, for 6 h. Brain magnetic resonance imaging (MRI) demonstrated acute ischemic lesions in the right frontal and parietal lobes, with restricted diffusion, hyperintense signal on fluid-attenuated inversion recovery, and reduced perfusion on mean transit time map, in the territory of the right middle cerebral artery. MR-angiography revealed an irregularity in the right middle cerebral artery flow signal. High-resolution intracranial vessel wall MRI showed a stenosis of the M1 segment of the right middle cerebral artery, with eccentric gadolinium-enhancement (Figure 1), suggestive of an unstable atherosclerotic plaque, responsible for the ischemic stroke. Despite the age, the patient had no other cardiovascular risk factors. The treatment was changed to imatinib as well as statin and anticoagulant were initiated due to ischemic attack. Nilotinib is a second-generation tyrosine-kinase inhibitor, which can be used as a first-line drug to treat chronic myeloid leukemia. The arterial occlusive disease is a well-known nilotinib adverse effect [1]. Previous studies demonstrated nilotinib-related cerebrovascular disease associated with one or multiple intracranial arterial stenosis, causing ischemic strokes [2]. The pathophysiological mechanisms of nilotinib-associated vascular adverse effects are not fully known. However, nilotinib has a high affinity for discoidin domain receptor-1, which plays a role in atherosclerosis formation, and it is a major blocker of platelet-derived growth factor receptor and C-kit, which regulate various vascular and perivascular cells. Furthermore, nilotinib exerts direct pro-atherogenic and anti-angiogenic effects, due to altered endothelial cell function and increased expression of cytoadhesive molecules. In addition, nilotinib increases cholesterol and fast glucose [2]. Intracranial atherosclerotic plaques typically appear as eccentric vessel wall thickening, with outward remodeling of the arterial wall, with heterogeneous signal, involving the proximal intracranial branches or bifurcation points. Intraplaque hemorrhage and/or eccentric gadolinium enhancement are signs of vulnerability and increased risk of stroke. These findings are important in patients with more than one intracranial atherosclerotic plaque, to evaluate the most vulnerable plaque or the responsible for a stroke. Also, vasculitis, an important differential diagnosis of atherosclerosis, would typically demonstrate concentric parietal thickening and gadolinium enhancement in the vessel wall [3], instead of an eccentric enhancement, as our patient. Therefore, intracranial vessel wall imaging may aid in the evaluation of patients with nilotinib-associated vascular adverse effects and should be added to the brain MRI protocol. Diogo Goulart Corrêa wrote the manuscript, assisted in taking original images, and produced the figure. Roberto Queiroz dos Santos assisted in taking original images, and provided valuable contributions to the manuscript. Luiz Celso Hygino da Cruz Jr. provided valuable contributions to the manuscript. The authors have no conflict of interest to disclose. There were no sources of funding for this manuscript. The information presented in this manuscript is deidentified, and there is no risk to the patient's privacy or confidentiality. IRB approval was not required by our institution for the preparation of this manuscript. Patient consent was obtained. No material from other sources is included in this manuscript. Data from this manuscript will be shared upon request." @default.
• W4386001080 created "2023-08-20" @default.
• W4386001080 creator A5026714604 @default.
• W4386001080 creator A5064576474 @default.
• W4386001080 creator A5082258563 @default.
• W4386001080 date "2023-08-17" @default.
• W4386001080 modified "2023-10-12" @default.
• W4386001080 title "Contribution of intracranial vessel wall magnetic resonance imaging in nilotinib‐associated vascular adverse effects diagnosis" @default.
• W4386001080 cites W2903150763 @default.
• W4386001080 cites W4324320302 @default.
• W4386001080 doi "https://doi.org/10.1002/jha2.775" @default.
• W4386001080 hasPublicationYear "2023" @default.
• W4386001080 type Work @default.
• W4386001080 citedByCount "0" @default.
• W4386001080 crossrefType "journal-article" @default.
• W4386001080 hasAuthorship W4386001080A5026714604 @default.
• W4386001080 hasAuthorship W4386001080A5064576474 @default.
• W4386001080 hasAuthorship W4386001080A5082258563 @default.
• W4386001080 hasBestOaLocation W43860010801 @default.
• W4386001080 hasConcept C126322002 @default.
• W4386001080 hasConcept C126838900 @default.
• W4386001080 hasConcept C127413603 @default.
• W4386001080 hasConcept C143409427 @default.
• W4386001080 hasConcept C164705383 @default.
• W4386001080 hasConcept C2777413986 @default.
• W4386001080 hasConcept C2777583451 @default.
• W4386001080 hasConcept C2778212899 @default.
• W4386001080 hasConcept C2778729363 @default.
• W4386001080 hasConcept C2780007028 @default.
• W4386001080 hasConcept C2780645631 @default.
• W4386001080 hasConcept C71924100 @default.
• W4386001080 hasConcept C78519656 @default.
• W4386001080 hasConceptScore W4386001080C126322002 @default.
• W4386001080 hasConceptScore W4386001080C126838900 @default.
• W4386001080 hasConceptScore W4386001080C127413603 @default.
• W4386001080 hasConceptScore W4386001080C143409427 @default.
• W4386001080 hasConceptScore W4386001080C164705383 @default.
• W4386001080 hasConceptScore W4386001080C2777413986 @default.
• W4386001080 hasConceptScore W4386001080C2777583451 @default.
• W4386001080 hasConceptScore W4386001080C2778212899 @default.
• W4386001080 hasConceptScore W4386001080C2778729363 @default.
• W4386001080 hasConceptScore W4386001080C2780007028 @default.
• W4386001080 hasConceptScore W4386001080C2780645631 @default.
• W4386001080 hasConceptScore W4386001080C71924100 @default.
• W4386001080 hasConceptScore W4386001080C78519656 @default.
• W4386001080 hasLocation W43860010801 @default.
• W4386001080 hasOpenAccess W4386001080 @default.
• W4386001080 hasPrimaryLocation W43860010801 @default.
• W4386001080 hasRelatedWork W1977177366 @default.
• W4386001080 hasRelatedWork W2004039806 @default.
• W4386001080 hasRelatedWork W2008225112 @default.
• W4386001080 hasRelatedWork W2033384062 @default.
• W4386001080 hasRelatedWork W2057734297 @default.
• W4386001080 hasRelatedWork W2161932315 @default.
• W4386001080 hasRelatedWork W2410348774 @default.
• W4386001080 hasRelatedWork W2789094568 @default.
• W4386001080 hasRelatedWork W3014327972 @default.
• W4386001080 hasRelatedWork W3176823109 @default.
• W4386001080 isParatext "false" @default.
• W4386001080 isRetracted "false" @default.
• W4386001080 workType "article" @default.